Bone involvement and osteoporosis in mastocytosis.

Abstract

Bone involvement is frequent in patients with systemic mastocytosis. Osteoporosis is the most prevalent bone manifestation, but diffuse osteosclerosis or focal osteolytic or osteosclerotic lesions are not infrequent. The risk of osteoporotic fractures is high, especially at the spine and in men. Routine measurements of bone mineral density and vertebral morphometry are warranted. The bone turnover markers indicate the involvement of complex bone metabolism in mastocytosis-related manifestations. Bisphosphonates represent the first-line treatment for osteoporosis-related mastocytosis.

• Authors: Maurizio Rossini, Roberta Zanotti, Ombretta Viapiana, Gaia Tripi, Giovanni Orsolini, Luca Idolazzi, Patrizia Bonadonna, Donatella Schena, Luis Escribano, Silvano Adami, Davide Gatti
• Journal: Immunology and allergy clinics of North America (Immunol Allergy Clin North Am) Vol. 34 Issue 2 Pg. 383-96 (May 2014) ISSN: 1557-8607 [Electronic] United States
• PMID: 24745681 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Bone Density Conservation Agents
• Diphosphonates

Topics

• Adult
• Bone Density
• Bone Density Conservation Agents (therapeutic use)
• Clinical Trials as Topic
• Diphosphonates (therapeutic use)
• Female
• Humans
• Male
• Mastocytosis, Systemic (complications, drug therapy, epidemiology, pathology)
• Middle Aged
• Osteoporosis (complications, drug therapy, epidemiology, pathology)
• Spine (pathology)